phrykt

Milestone Pharmaceuticals Inc. (MIST): who owns it and who trades it

As of Nov 16, 2026, MIST insiders reported 9 open-market sales worth $860K and no purchases in the last 12 months, with 21% of the sale value made under pre-set 10b5-1 plans. The largest seller was Joseph Oliveto (CEO), with $556K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Milestone Pharmaceuticals

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns MIST

78 funds and institutions reported MIST shares worth $68.1M at the end of Q2 2026, about 43% of the company. The largest holder is Pavaki Capital Management LLC with 7.7%.

Funds and institutions (13F) 43%Everyone else 57%

10 largest owners, by share of the company

Pavaki Capital Management LLC7.7%
Rtw Investments, LP6.7%
Propel Bio Management, LLC6.3%
Point72 Asset Management, L.P.4.6%
Simplify Asset Management Inc.2.8%
Millennium Management LLC2.7%
Kalehua Capital Management LLC2.2%
Two Sigma Investments, LP1.7%
Marshall Wace, LLP1.5%
Lion Point Capital, LP0.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Pavaki Capital Management LLC9.07M7.71%$12.2MNew
Rtw Investments, LP7.83M6.66%$10.5M+24%
Propel Bio Management, LLC7.43M6.31%$10M+80%
Point72 Asset Management, L.P.5.41M4.60%$7.3M+398%
Simplify Asset Management Inc.3.35M2.85%$4.5M+122%
Millennium Management LLC3.14M2.67%$4.2M+103%
Kalehua Capital Management LLC2.54M2.16%$3.4MNew
Two Sigma Investments, LP2.04M1.73%$2.7M-12%
Marshall Wace, LLP1.80M1.53%$2.4M-8%
Lion Point Capital, LP820,0000.70%$1.1MNo change
Toronto Dominion Bank750,0000.64%$1MNo change
Boxer Capital Management, LLC666,6660.57%$893KNo change
Ameriprise Financial Inc666,6660.57%$893KNew
Morgan Stanley635,2110.54%$851K-12%
UBS Group AG465,4030.40%$624K-6%
Boothbay Fund Management, LLC462,6690.39%$620K+174%
Susquehanna International Group, LLP359,8950.31%$482K-31%
Guardian Wealth Advisors, LLC / Nc339,4500.29%$455K+21%
Aptus Capital Advisors, LLC339,4500.29%$455K+21%
Seven Fleet Capital Management LP270,2330.23%$362K-19%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, MIST insiders reported $0 of open-market purchases and $860K of sales. 21% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$860K
9 trades, 3 people
Sales under a 10b5-1 plan
21%
Share of sale value
Latest trade
Apr 16, 2026
Filed Apr 20, 2026

Purchases and sales by month

$568K$568KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Apr 16, 2026Joseph OlivetoCEOSale plan36,500$2.26$82.5KForm 4
Jan 26, 2026David BharuchaChief Medical OfficerSale12,245$1.93$23.6KForm 4
Jan 26, 2026Lorenz MullerChief Commercial OfficerSale11,180$1.93$21.6KForm 4
Jan 26, 2026Joseph OlivetoCEOSale34,523$1.93$66.6KForm 4
Jan 8, 2026Joseph OlivetoCEOSale plan43,000$2.25$96.8KForm 4
Jan 7, 2026Joseph OlivetoCEOSale plan500$2.25$1.1KForm 4
Dec 15, 2025David BharuchaChief Medical OfficerSale58,007$2.32$135KForm 4
Dec 15, 2025Lorenz MullerChief Commercial OfficerSale53,566$2.32$124KForm 4
Dec 15, 2025Joseph OlivetoCEOSale133,054$2.32$309KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Joseph OlivetoPresident and CEO, Director–$556KApr 16, 2026
David BharuchaChief Medical Officer–$158KJan 26, 2026
Lorenz MullerChief Commercial Officer–$146KJan 26, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

MIST short interest

High short interest. 16.0% of MIST shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 166%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 19.90M MIST shares were sold short, 16.0% of the shares outstanding, up 0.9% from the report before. At the average daily volume of 801,259 shares, buying them all back would take about 24.8 trading days (days to cover).

Shares short, % of all shares

16.0%May 15Oct 3017.4%

Days to cover

24.8May 15Oct 3027.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202619.90M15.98%+1%801,25924.8
Oct 15, 202619.71M15.83%+4%1.05M18.7
Sep 30, 202619.01M15.27%+4%1.19M16.0
Sep 15, 202618.36M14.75%+6%1.73M10.6
Aug 31, 202617.36M13.95%+4%1.53M11.3
Aug 14, 202616.64M13.36%+6%1.77M9.4
Jul 31, 202615.69M13.33%+8%1.23M12.7
Jul 15, 202614.58M12.39%+16%1.07M13.6
Jun 30, 202612.60M10.71%+19%1.68M7.5
Jun 15, 202610.60M9.01%+15%1.22M8.7
May 29, 20269.19M7.81%+23%1.17M7.8
May 15, 20267.48M6.36%-4%1.75M4.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Milestone Pharmaceuticals company events

Milestone Pharmaceuticals filed 10 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, listing). The latest was on Oct 28, 2026.

  1. Oct 28, 2026ListingMilestone Pharmaceuticals Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the listing of its common shares was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Select Market… Filing
  2. Sep 3, 2026AnnouncementMilestone Pharmaceuticals Inc. issued a press release announcing that China’s National Medical Products Administration has approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) in adults. Filing
  3. Aug 12, 2026ResultsReleased financial results. Filing
  4. Jun 15, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers. Filing
  5. May 13, 2026ResultsReleased financial results. Filing
  6. Mar 20, 2026ResultsReleased financial results. Filing
  7. Jan 26, 2026AnnouncementMilestone Pharmaceuticals Inc. issued a press release announcing the availability of CARDAMYST (etripamil) nasal spray for the management of paroxysmal supraventricular tachycardia (PSVT) in the United States. Filing
  8. Jan 13, 2026AnnouncementAs previously disclosed, on March 27, 2023, Milestone Pharmaceuticals Inc. entered into a Purchase and Sale Agreement (as amended, the “Royalty Purchase Agreement”) with RTW Royalty I DAC, an affiliate of RTW Investments, LP, pursuant to which funds managed by RTW agreed to purchase, following U.S.… Filing
  9. Jan 6, 2026AnnouncementThe Company issued a press release announcing the acceptance of a Marketing Authorization Application by the European Medicines Agency seeking the approval of etripamil nasal spray. Filing
  10. Dec 15, 2025AnnouncementThe Company issued a press release announcing that the U.S. Food and Drug Administration has approved the Company’s New Drug Application for CARDAMYST (etripamil) nasal spray for the management of paroxysmal supraventricular tachycardia (PSVT). Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Milestone Pharmaceuticals financials

Famous investors that hold MIST

3 of the 50 well-known investors we track reported holding MIST in their latest 13F filing. The largest position is Steve Cohen's, worth $4.7M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20265.47M$4.7M0.0%+1%
Israel Englander · Millennium ManagementQ3 20262.24M$1.9M0.0%-29%
Ken Griffin · Citadel AdvisorsQ3 202634,375$29.8K0.0%+5%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Milestone Pharmaceuticals Inc. (MIST) stock

Who owns the most MIST stock?

The largest reported owner of Milestone Pharmaceuticals Inc. (MIST) is Pavaki Capital Management LLC, with 7.7% of the company. In total, 78 funds and institutions reported holding MIST at the end of Q2 2026, together about 43% of the shares. See the largest owners.

Are MIST insiders buying or selling?

In the last 12 months, MIST insiders reported no open-market purchases and 9 sales worth $860K. The latest trade was on Apr 16, 2026. See every trade.

What is the short interest in MIST?

As of Oct 30, 2026, 19.90M MIST shares were sold short, 16.0% of the shares outstanding, up 0.9% from the report before. At the average daily volume of 801,259 shares, buying them all back would take about 24.8 trading days (days to cover). See the history.

Which famous investors hold MIST?

3 of the 50 well-known investors we track reported MIST in their latest 13F filing, including Steve Cohen, Israel Englander, Ken Griffin. The largest position is worth $4.7M. See all holders.

Executive pay

Milestone Pharmaceuticals's chief executive was paid a total of $2.1M for the year ended Dec 31, 2025, up 148% from $854K the year before. In the last 12 months, Milestone Pharmaceuticals's executives and directors bought no stock on the open market and sold $860K.

Chief executive, total pay$2.1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$2.9MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.